Physician profile
Ratul Chatterjee
NPI 1770597387
$15,514.02
in general payments reported to CMS, 2019-2025
35 companies · $868 in 2025
The $868 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,976 · 2020: $3,060 · 2021: $1,212 · 2022: $1,140 · 2023: $1,349 · 2024: $909 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,126.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $4,656.11 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $1,903.46 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $1,290.23 | 2019-2021 | |
| Lilly USA, LLC | $1,016.68 | 2019-2025 | Mounjaro |
| Amgen INC. | $928.57 | 2019-2025 | Evenity, Prolia, Otezla |
| Pfizer INC. | $599.84 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $471.94 | 2019-2023 | Verquvo |
| Glaxosmithkline, LLC. | $451.96 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $449.13 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $374.44 | 2025 | Zenpep |
| Bayer Healthcare Pharmaceuticals INC. | $342.98 | 2021-2023 | |
| Amarin Pharma, INC. | $326.68 | 2019 | |
| Novo Nordisk INC | $323.26 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Biohaven Pharmaceuticals, INC. | $278.31 | 2021 | |
| Radius Health, INC. | $276.71 | 2020-2025 | Tymlos |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $241.86 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $151.08 | 2019-2024 | Eliquis |
| Sanofi-Aventis U.S. LLC | $150.33 | 2019 | |
| Horizon Therapeutics Plc | $142.63 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.74 | 2020-2023 | Ofev |
| Sanofi Pasteur INC. | $127.24 | 2019 | |
| Nestle Healthcare Nutrition INC. | $124.98 | 2023 | |
| Phathom Pharmaceuticals, INC. | $124.26 | 2025 | Voquezna |
| Acadia Pharmaceuticals INC | $119.51 | 2019 | |
| Lundbeck LLC | $114.87 | 2019-2024 | Rexulti |
| Eisai INC. | $69.74 | 2020-2022 | |
| Astellas Pharma US INC | $65.61 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $52.51 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.07 | 2021 | |
| Abbvie INC. | $40.03 | 2020-2021 | |
| Esperion Therapeutics, INC. | $31.61 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $31.15 | 2020 | |
| Scilex Pharmaceuticals INC. | $22.02 | 2024 | |
| Circassia INC. | $17.49 | 2019 | |
| Exact Sciences Corporation | $15.99 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ratul Chatterjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.